

MICROMET, INC.  
Form 8-K  
November 02, 2007

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

October 29, 2007

Micromet, Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-50440

522243564

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I.R.S. Employer  
Identification No.)

6707 Democracy Boulevard, Suite 505,  
Bethesda, Maryland

20817

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(240) 752-1420

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Top of the Form**

**Item 1.01 Entry into a Material Definitive Agreement.**

On October 29, 2007, Micromet, Inc. (the "Company") and Merck Serono International SA ("Merck Serono") executed a Second Amendment (the "Amendment") to their Collaboration and License Agreement dated December 3, 2004, as amended as of November 24, 2006 (as so amended, the "Collaboration Agreement"). The Amendment is made effective as of October 19, 2007. Under the Amendment, the parties have reallocated certain of their respective development responsibilities with respect to the product candidate adecatumumab (MT201). As part of the revised responsibilities, the Company will have all decision making authority and operational responsibility for the Phase 1b clinical trial currently being conducted to evaluate the combination of MT201 and docetaxel in patients with metastatic breast cancer, as well as an additional clinical trial to be conducted by the Company. Merck Serono will continue to bear the development expenses associated with the collaboration pursuant to the Collaboration Agreement in accordance with the agreed upon budget.

---

**Top of the Form**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Micromet, Inc.

*November 2, 2007*

By: */s/ Matthias Alder*

---

*Name: Matthias Alder*

*Title: Senior Vice President & General Counsel*